PTH10: EVALUATING PHARMACEUTICAL COSTS OF PATIENTS WITH CHRONIC LUNG DISEASE IN GERMAN IN- AND OUTPATIENTS SETTING  by Hessel, F & Wasem, J
Abstracts 407
ing inhaled corticosteroids. Within 3 months of starting
zafirlukast, outpatient visits, inpatient stays, emergency de-
partment visits, and albuterol prescriptions were all signifi-
cantly reduced compared with the previous 3 months (p 
0.002). In the 3 months before starting zafirlukast, 55%
of patients received oral corticosteroids, compared with
15% in the 3 months after commencing zafirlukast.
CONCLUSIONS: Retrospective data analysis may be
valuable in determining how therapies are used in clinical
practice and in measuring the effectiveness of asthma ther-
apies outside of controlled clinical trials. This study shows
that the addition of zafirlukast to existing asthma regi-
mens was associated with reduced healthcare utilisation
and reduced need for oral corticosteroids and albuterol,
which may translate into reduced direct healthcare costs.
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OBJECTIVES: Costs for medication are beside productiv-
ity loss most relevant for patients with chronic lung disease
like asthma and COLD. In Germany hospital prices for
pharmaceuticals are not fixed by the government and not
accessible through administrative data. Official sales-prices
(Rote Liste) do not represent opportunity costs.
METHODS: To improve the evaluation of medication
costs we calculated the resources used by measuring the
units of 100 fully hospitalized patients of a rehabilitation
clinic for chronic lung diseases and validated with unit
prices from Rote Liste. These costs were compared with
average expenses for medication per day according to the
clinic’s routine calculation. To assess medication costs in
an outpatient setting we used a cost diary, where patients
note all health care resource uses, and a standardized ret-
rospective questionnaire.
RESULTS: Medication costs in inpatient rehabilitation
setting were 11,4 DM per day (SD 5,0) validated by Rote
Liste. Actual average expenses for the clinic were 2,8 DM
(Rate: 1:4). Medication costs in outpatient setting were
260 DM per month according to the cost diary (n  28)
and 270 DM using the questionnaire (n  41). Dropouts
were remarkably higher using the diary (44%), compared
to the questionnaire (18%).
CONCLUSIONS: Investigators should be aware of the
fact, that the difference between medication costs vali-
dated by sales prices and hospital expenses can be crucial
for the result of an economic evaluation especially for
chronic diseases with mainly pharmaceutical therapy. In
an acute hospital setting this difference might even be
higher, further research is necessary. To assess medication
costs in an outpatient setting a retrospective questionnaire
seems to be the most reliable and practicable way.
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OBJECTIVES: We currently have over 2,000 active pre-
scriptions for albuterol inhalers. Improper use could render
medication not effective and result in over prescribing. At
an average wholesale price of $25.00 per inhaler the cost is
not insignificant. We wanted to know if patients with air-
way obstruction were able to deliver medication through
their inhaler correctly and whether monitoring would be
cost effective in terms of training and education cost.
METHODS: We sampled thirty-eight consecutive patients
in pulmonary clinic with chronic obstructive pulmonary dis-
ease being treated with albuterol metered does inhalers.
Assessment was performed using an aerosol inhalation
monitor and observation. Critical steps evaluated in the
maneuver: 1. Shaking canister, 2. Begin inspiration between
functional residual capacity and residual volume, 3. Firing
of inhaler and synchrony with inspiration, and 4. Breath
hold time. Inhaler performance, costs of medication, and
training costs were evaluated using Decisional Analysis soft-
ware (Data 3.5).
RESULTS: Only thirty three percent of patients could per-
form the inhaler technique correctly on screening. Sixty
seven percent failed and underwent training; of this group
which failed ninety seven percent passed after training.
CONCLUSIONS: We found this process of inhaler mon-
itoring to be cost effective for our patient population.
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OBJECTIVES: The objective of this study was to collect
information about health care resources used in the In-
tensive Care Unit (ICU) to treat pediatric patients with
acute respiratory distress syndrome, and to calculate to-
tal treatment costs. To collect this information, the use of
administrative databases or hospital records was consid-
ered. The latter method was used. Costs for each re-
source were estimated through micro and gross costing.
METHODS: A non-comparative retrospective cohort study
was conducted using hospital records. The study popula-
tion was comprised of pediatric patients treated in the
ICU of the Sainte-Justine Hospital. Selected were ninety-
six (96) patients who required ventilation support fol-
lowing acute respiratory distress syndrome in 1996. All
hospital files were reviewed to collect data on patient
